ATE222119T1 - Verwendung von erythropoietin zur behandlung von multiple myelom - Google Patents

Verwendung von erythropoietin zur behandlung von multiple myelom

Info

Publication number: ATE222119T1
Authority: AT; Austria
Prior art keywords: erythropoietin; multiple myeloma; treat multiple; cancer; inhibition
Prior art date: 1998-04-08

Application number

AT99912039T

Other languages

English (en)

Inventor

Nechama Haran-Ghera

Moshe Mittelman

Alpha Peled

Original Assignee

Yeda Res & Dev

Mor Research Applic Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-08

Filing date

1999-03-30

Publication date

2002-08-15

1999-03-30 Application filed by Yeda Res & Dev, Mor Research Applic Ltd filed Critical Yeda Res & Dev

2002-08-15 Application granted granted Critical

2002-08-15 Publication of ATE222119T1 publication Critical patent/ATE222119T1/de

Links

102000003951 Erythropoietin Human genes 0.000 title abstract 3
108090000394 Erythropoietin Proteins 0.000 title abstract 3
229940105423 erythropoietin Drugs 0.000 title abstract 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 3
208000034578 Multiple myelomas Diseases 0.000 title abstract 2
206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 4
201000011510 cancer Diseases 0.000 abstract 3
230000005764 inhibitory process Effects 0.000 abstract 2
206010027476 Metastases Diseases 0.000 abstract 1
230000007123 defense Effects 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99912039T 1998-04-08 1999-03-30 Verwendung von erythropoietin zur behandlung von multiple myelom ATE222119T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL12401598A IL124015A0 (en)	1998-04-08	1998-04-08	Pharmaceutical compositions comprising a protein
PCT/IL1999/000186 WO1999052543A2 (en)	1998-04-08	1999-03-30	Pharmaceutical compositions comprising erythropoietin for treatment of cancer

Publications (1)

Publication Number	Publication Date
ATE222119T1 true ATE222119T1 (de)	2002-08-15

Family

ID=11071408

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99912039T ATE222119T1 (de)	1998-04-08	1999-03-30	Verwendung von erythropoietin zur behandlung von multiple myelom

Country Status (10)

Country	Link
US (2)	US6579525B1 (de)
EP (1)	EP1067955B1 (de)
JP (1)	JP4456271B2 (de)
AT (1)	ATE222119T1 (de)
AU (1)	AU3052799A (de)
CA (1)	CA2366674C (de)
DE (1)	DE69902523T2 (de)
ES (1)	ES2185323T3 (de)
IL (2)	IL124015A0 (de)
WO (1)	WO1999052543A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60131393D1 (de) *	2000-05-02	2007-12-27	Action Pharma As	Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
DE10219545A1 (de) *	2002-04-26	2003-11-06	Lang Florian	Regulation der Apoptose
ATE451924T1 (de)	2004-03-15	2010-01-15	Sunesis Pharmaceuticals Inc	Sns-595 und anwendungsverfahren
US7588745B2 (en) *	2004-04-13	2009-09-15	Si Options, Llc	Silicon-containing products
WO2006006165A2 (en) *	2004-07-12	2006-01-19	Yeda Research And Development Co. Ltd.	Use of erythropoietin for enhancing immune responses and for treatment of lymphoproliferative disorders
US8580814B2 (en) *	2006-04-03	2013-11-12	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8124773B2 (en)	2006-06-12	2012-02-28	Sunesis Pharmaceuticals, Inc.	1,8-naphthyridine compounds for the treatment of cancer
WO2009094172A2 (en)	2008-01-22	2009-07-30	Araim Pharmaceuticals, Inc.	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
SG188143A1 (en)	2008-02-08	2013-03-28	Ambrx Inc	Modified leptin polypeptides and their uses
EP2318029B1 (de)	2008-07-23	2017-11-01	Ambrx, Inc.	Modifizierte bovine g-csf-polypeptide und ihre verwendung
US8278418B2 (en)	2008-09-26	2012-10-02	Ambrx, Inc.	Modified animal erythropoietin polypeptides and their uses
EA013806B1 (ru) *	2009-04-01	2010-08-30	Общество С Ограниченной Ответственностью "Лэнс-Фарм"	Применение эритропоэтина для лечения миелобластного лейкоза
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
CN105517561A (zh) *	2013-07-17	2016-04-20	阿拉伊姆药品公司	预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CA2954975C (en)	2014-06-12	2023-09-05	Andremacon S.R.L.	Use of negative functional modulators of erythropoietin for therapy
PL230756B1 (pl) *	2015-09-11	2018-12-31	Univ Medyczny W Bialymstoku	Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
CN106075447B (zh) *	2016-06-24	2018-07-10	中国人民解放军第二军医大学	一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用
WO2025071560A1 (en) *	2023-09-28	2025-04-03	Rutgers, The State University Of New Jersey	Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU646822B2 (en) *	1989-10-13	1994-03-10	Kirin-Amgen Inc.	Erythropoietin isoforms
US6012450A (en) *	1993-01-29	2000-01-11	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
US20020052309A1 (en)	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury

1998
- 1998-04-08 IL IL12401598A patent/IL124015A0/xx unknown
1999
- 1999-03-30 AU AU30527/99A patent/AU3052799A/en not_active Abandoned
- 1999-03-30 AT AT99912039T patent/ATE222119T1/de active
- 1999-03-30 US US09/647,761 patent/US6579525B1/en not_active Expired - Lifetime
- 1999-03-30 WO PCT/IL1999/000186 patent/WO1999052543A2/en not_active Ceased
- 1999-03-30 DE DE69902523T patent/DE69902523T2/de not_active Expired - Lifetime
- 1999-03-30 ES ES99912039T patent/ES2185323T3/es not_active Expired - Lifetime
- 1999-03-30 EP EP99912039A patent/EP1067955B1/de not_active Expired - Lifetime
- 1999-03-30 JP JP2000543153A patent/JP4456271B2/ja not_active Expired - Fee Related
- 1999-03-30 CA CA2366674A patent/CA2366674C/en not_active Expired - Fee Related
2000
- 2000-09-26 IL IL138705A patent/IL138705A/en not_active IP Right Cessation
2003
- 2003-03-05 US US10/378,970 patent/US20030216316A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1999052543A2 (en)	1999-10-21
US6579525B1 (en)	2003-06-17
ES2185323T3 (es)	2003-04-16
DE69902523D1 (de)	2002-09-19
HK1033910A1 (en)	2001-10-05
CA2366674C (en)	2010-12-21
EP1067955B1 (de)	2002-08-14
AU3052799A (en)	1999-11-01
IL124015A0 (en)	1999-01-26
DE69902523T2 (de)	2003-04-24
EP1067955A2 (de)	2001-01-17
CA2366674A1 (en)	1999-10-21
WO1999052543A3 (en)	1999-12-16
JP4456271B2 (ja)	2010-04-28
IL138705A (en)	2007-02-11
US20030216316A1 (en)	2003-11-20
JP2002511419A (ja)	2002-04-16

Similar Documents

Publication	Publication Date	Title
DE69902523D1 (de)	2002-09-19	Verwendung von erythropoietin zur behandlung von multiple myelom
DE59903921D1 (de)	2003-02-06	Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ATE415962T1 (de)	2008-12-15	Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
EA199800391A1 (ru)	1999-10-28	Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
ATE279181T1 (de)	2004-10-15	Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE241358T1 (de)	2003-06-15	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
TR200201051T2 (tr)	2002-09-23	Tirosin kinaz inhibitörleri.
DE69830072D1 (de)	2005-06-09	Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE440618T1 (de)	2009-09-15	Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
ATE230607T1 (de)	2003-01-15	Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE527022T1 (de)	2011-10-15	Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
ATE249220T1 (de)	2003-09-15	Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
ATE411016T1 (de)	2008-10-15	Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE60118889D1 (de)	2006-05-24	Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE60032795D1 (de)	2007-02-15	Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE238792T1 (de)	2003-05-15	Verwendung von makroliden zur behandlung von glaukom
DE69918972D1 (de)	2004-09-02	Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE271873T1 (de)	2004-08-15	Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
EA200500934A1 (ru)	2006-04-28	Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
DE60123138D1 (de)	2006-10-26	Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE261724T1 (de)	2004-04-15	Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE60131968D1 (de)	2008-01-31	PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE59900286D1 (de)	2001-10-31	Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE279918T1 (de)	2004-11-15	Verwendung von aloe-emodin zur behandlung von neuroektodermalen tumoren
ATE278401T1 (de)	2004-10-15	Verwendung von riluzol zur behandlung von akustischen traumazuständen

Legal Events

Date

Code

Title

Description

2003-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1067955

Country of ref document: EP